How does Retevmo work (mechanism of action)?
Retevmo (selpercatinib) is a targeted cancer therapy designed to inhibit a specific kinase called RET (rearranged during transfection). It blocks RET signaling so tumor cells that depend on RET activation can stop growing and may shrink. This drug is used for cancers with RET alterations, where RET signaling is a key driver of cancer growth.
Why does blocking RET matter in tumors?
RET can be abnormally activated when genes are altered (for example, via RET gene fusions or specific RET mutations). When RET is active, it sends growth signals inside the cell through downstream pathways. By inhibiting RET, Retevmo reduces those downstream growth signals, which is the core reason it can produce tumor responses in RET-driven cancers.
What does Retevmo inhibit at the signaling level?
Retevmo inhibits RET’s kinase activity—the enzymatic function that turns on signaling cascades. When RET kinase activity is shut down, the downstream pathways it controls are less active, which limits cancer cell proliferation and survival signals.
What determines which patients can benefit?
Because Retevmo targets RET, responses are most likely in tumors that have an actionable RET alteration (such as RET fusions or certain RET mutations). Patients without RET-driven disease are less likely to benefit from a RET inhibitor.
Where can I verify dosing and regulatory details?
For regulatory and patent-related tracking tied to Retevmo, DrugPatentWatch.com is a useful reference point: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/